NASDAQ:RNA

Avidity Biosciences Q4 2024 Earnings Results & Report

Avidity Biosciences logo
$6.43 -1.08 (-14.38%)
As of 04:00 PM Eastern

Avidity Biosciences missed analyst earnings expectations but beat on revenue in its Q4 2024 results, released February 27, 2025. The company reported EPS of -$0.80 versus the -$0.76 consensus estimate, while revenue of $2.97 million topped the $1.74 million estimate by $1.23 million.

Earnings Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call
2:00 AM ET

Avidity Biosciences EPS Results

Actual EPS
-$0.80
Consensus EPS
-$0.76
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Avidity Biosciences Revenue Results

Actual Revenue
$2.97 million
Expected Revenue
$1.74 million
Beat/Miss
Beat by +$1.23 million
YoY Revenue Growth
N/A

Avidity Biosciences Q4 2024 Earnings FAQ

Avidity Biosciences (NASDAQ:RNA) reported earnings of -$0.80 per share for Q4 2024, missing the consensus estimate of -$0.76. The report was announced on Thursday, February 27, 2025.

Avidity Biosciences reported revenue of $2.97 million for Q4 2024, against a consensus estimate of $1.74 million.

Avidity Biosciences Earnings Headlines

Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
Avidity Biosciences (RNA) Expected to Post Earnings on Thursday
See More Avidity Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avidity Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avidity Biosciences and other key companies, straight to your email.

About Avidity Biosciences

Avidity Biosciences (NASDAQ:RNA) is a biotechnology company focused on developing RNA-based medicines for diseases that affect muscle. Its Antibody Oligonucleotide Conjugate (AOC) platform combines antibodies with oligonucleotides to help deliver RNA-targeting treatments into muscle cells.

The company’s research and clinical pipeline has included programs for neuromuscular disorders such as myotonic dystrophy type 1 and Duchenne muscular dystrophy. Avidity was founded in 2012 and is based in San Diego, California.

View Avidity Biosciences Profile